Systemic Lupus Erythematosus

Detailed Overview

SLE is the prototype of a systemic autoimmune disease. It is marked by a vast array of autoantibodies, particularly antinuclear antibodies (ANA), which target intracellular antigens. The pathophysiology involves defective clearance of apoptotic cells, triggering an abnormal immune response. Clinical manifestations range from mild mucocutaneous and joint involvement to life-threatening lupus nephritis and cerebritis. The disease runs a completely unpredictable course of flares and remissions.

Epidemiology & Demographics

Prevalence is roughly 20-150 per 100,000. Striking female predominance, particularly during reproductive years (female-to-male ratio of 9:1). Higher incidence and more severe disease observed in African American, Hispanic, and Asian populations.

Etiological Mechanism

A multifactorial interplay of genetic susceptibility (HLA-DR2, HLA-DR3, complement deficiencies like C1q, C2, C4), hormonal factors (estrogen), and environmental triggers (ultraviolet light, Epstein-Barr virus, silica dust).

Primary Causes

Loss of self-tolerance leading to autoantibody production. Environmental triggers like UV light cause keratinocyte apoptosis; defective clearance of these apoptotic cells exposes nuclear antigens to the immune system, initiating the autoimmune cascade.

• Sex: Being female of childbearing age due to the immunomodulatory effects of estrogen and prolactin.
• Genetics: First-degree relatives have a 20-fold increased risk. Deficiencies in early complement components (C1q, C4, C2) strongly predispose to SLE.
• UV Radiation: Sunlight exposure can induce flares by increasing apoptosis in the skin.
• Medications (Drug-Induced Lupus): Hydralazine, Procainamide, Isoniazid, and Minocycline can cause a reversible lupus-like syndrome (usually sparing kidneys/CNS).

Defective clearance of apoptotic bodies leads to an accumulation of autoantigens (DNA, histones, RNPs). B cells lose tolerance and produce IgG autoantibodies against these antigens (e.g., anti-dsDNA, anti-Sm). These autoantibodies bind to their circulating targets to form immune complexes (Type III hypersensitivity). These complexes deposit in vascular beds (glomeruli, dermis, synovium, choroid plexus) where they activate the classical complement pathway. This consumes complement proteins (leading to low C3/C4) and triggers an influx of neutrophils and macrophages, causing intense localized tissue inflammation and damage. Additionally, autoantibodies can directly attack cells, such as red blood cells or platelets (Type II hypersensitivity), causing cytopenias.

Characteristic Clinical Presentation

• Constitutional: Overwhelming fatigue, low-grade fevers, and unexplained weight loss.
• Joint Pain: Migratory, symmetrical polyarthritis and arthralgia (often non-erosive, known as Jaccoud arthropathy).
• Skin Rashes: Photosensitive rashes worsening after sun exposure.
• Chest Pain: Pleuritic chest pain due to pleuritis or pericarditis.

Physical Examination Signs

• Malar Rash
• Discoid Rash
• Oral Ulcers
• Alopecia

• Lupus Nephritis: Immune complex glomerulonephritis occurring in up to 50% of patients, leading to nephrotic syndrome or end-stage renal disease (ESRD).
• Cardiovascular Disease: Premature, accelerated atherosclerosis resulting in early myocardial infarction. Libman-Sacks endocarditis (non-bacterial verrucous vegetations).
• Antiphospholipid Syndrome (APS): Secondary APS causes recurrent arterial/venous thromboses and recurrent spontaneous miscarriages.

Diagnostic Criteria & Guidelines

Diagnosed using the 2019 EULAR/ACR classification criteria. Requires an ANA titer >= 1:80 as an entry criterion. Then, weighted points are assigned across clinical domains (fever, skin, joints, neuro, serositis, renal) and immunologic domains (anti-dsDNA, anti-Sm, low C3/C4, positive antiphospholipid antibodies). A score of >= 10 confirms SLE.

Differential Diagnosis

• Rheumatoid Arthritis
• Sjogren's Syndrome
• Dermatomyositis
• Fibromyalgia
• Mixed Connective Tissue Disease (MCTD)

Laboratory Tests & Biomarkers

• ANA (Antinuclear Antibody): Positive in >98% of patients. Highly sensitive, but low specificity.
• Anti-dsDNA: Highly specific. Titers fluctuate with disease activity and correlate strongly with lupus nephritis.
• Anti-Sm (Smith): Most specific antibody for SLE (99% specific) but only present in 20-30% of patients. Titers do not correlate with disease activity.
• Complement C3 and C4: Low levels indicate active systemic inflammation and complement consumption.

Imaging Modalities & Findings

• Renal Biopsy: Gold standard for suspected lupus nephritis. Shows 'full house' immunofluorescence (IgG, IgA, IgM, C3, C1q deposition) and variable mesangial, endothelial, or podocyte damage depending on WHO Class (I-VI).
• Echocardiogram: Pericardial effusion (common) or sterile valvular vegetations (Libman-Sacks).

• Mild
  Involvement limited to skin, joints, and mucosa. Normal organ function.
• Moderate
  Significant cutaneous/articular disease poorly responsive to initial therapy, or mild hematologic cytopenias.
• Severe
  Life-threatening or organ-threatening involvement: Lupus nephritis, cerebritis, severe hemolytic anemia, or pulmonary hemorrhage.

Second-Line & Adjunctive Therapy

For moderate-to-severe disease: Immunosuppressants such as Azathioprine, Methotrexate, or Mycophenolate mofetil. Biologics like Belimumab (BAFF inhibitor) or Anifrolumab (Type I IFN receptor antagonist) are used for refractory skin/joint disease. For severe Lupus Nephritis (Class III/IV): Induction therapy with High-dose IV Corticosteroids (Methylprednisolone 1g/day for 3 days) plus either IV Cyclophosphamide or PO Mycophenolate mofetil.

Surgical & Procedural Management

Renal transplantation for end-stage renal disease secondary to lupus nephritis. Joint replacements for avascular necrosis (a common complication of chronic high-dose steroid use).

Recommended Lifestyle Changes

• Strict photoprotection: Daily use of broad-spectrum sunscreen (SPF 50+), protective clothing, and sun avoidance.
• Smoking cessation: Smoking blunts the efficacy of hydroxychloroquine and accelerates cutaneous lupus.
• Ensure adequate Calcium and Vitamin D intake to prevent steroid-induced osteoporosis.

Patient Counseling & Advice

Pregnancy must be planned during periods of disease quiescence (inactive for >6 months), as active lupus severely threatens both maternal and fetal survival. Anti-Ro/SSA antibodies can cross the placenta and cause neonatal lupus with congenital heart block. Stress the importance of never abruptly stopping corticosteroids.

Follow-Up & Monitoring Schedule

Routine monitoring every 3-6 months. Check blood pressure, urinalysis (for proteinuria/cellular casts), spot Urine Protein-to-Creatinine ratio, CBC, basic metabolic panel, Anti-dsDNA titers, and C3/C4 levels to predict flares.

Preventive Strategies

Sun protection is the primary preventive measure against cutaneous and systemic flares. Vaccination (pneumococcal, influenza) is critical as infection is a leading cause of death due to immunosuppression.

Survival has improved dramatically; 10-year survival is now >90%. However, patients face significant morbidity from chronic organ damage and medication side effects (especially steroids). Bimodal mortality: early death from active disease/infection, late death from accelerated cardiovascular disease.